We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Halozyme (HALO) Run Higher on Strong Earnings Estimate Revisions?
Read MoreHide Full Article
Halozyme Therapeutics, Inc. (HALO - Free Report) is a therapeutically driven, development stage biopharmaceutical company, which could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on HALO’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Halozyme could be a solid choice for investors.
Current Quarter Estimates for HALO
In the past 30 days, three estimates have gone higher for Halozyme while one has gone lower in the same time period. The trend has been pretty favorable too, with estimates increasing from a loss of 27 cents a share 30 days ago, to earnings of 54 cents today.
Current Year Estimates for HALO
Meanwhile, Halozyme’s current year figures are also looking quite promising, with four estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of $1.03 per share 30 days ago to a loss of 5 cents per share today, an increase of 95.1%.
The stock has also started to move higher lately, adding 37.2% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #2 (Buy) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure.
Image: Bigstock
Can Halozyme (HALO) Run Higher on Strong Earnings Estimate Revisions?
Halozyme Therapeutics, Inc. (HALO - Free Report) is a therapeutically driven, development stage biopharmaceutical company, which could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on HALO’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Halozyme could be a solid choice for investors.
Current Quarter Estimates for HALO
In the past 30 days, three estimates have gone higher for Halozyme while one has gone lower in the same time period. The trend has been pretty favorable too, with estimates increasing from a loss of 27 cents a share 30 days ago, to earnings of 54 cents today.
Current Year Estimates for HALO
Meanwhile, Halozyme’s current year figures are also looking quite promising, with four estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of $1.03 per share 30 days ago to a loss of 5 cents per share today, an increase of 95.1%.
Halozyme Therapeutics, Inc. Price and Consensus
Halozyme Therapeutics, Inc. Price and Consensus | Halozyme Therapeutics, Inc. Quote
Bottom Line
The stock has also started to move higher lately, adding 37.2% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #2 (Buy) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure.
See these buy recommendations now >>